Biotechnology

Facing delisting, Virax Biolabs consolidates its shares in a bid to survive. This move buys time, but the real test lies in its innovative T-cell technology.

A key FDA alignment for zervimesine not only de-risks a pivotal trial but signals a new era for treating the devastating psychosis of an overlooked dementia.

With M&A veterans Martin Babler and Troy Cox joining its board, MapLight Therapeutics is signaling a strategic shift from foundational research to late-stage execution.

An alliance of biopharma innovators is set to discuss a critical hurdle in medicine: delivering RNA therapies to tissues beyond the liver, a key to unlocking new treatments.

Novartis is betting nearly $2 billion on Antares Therapeutics' novel platform to conquer historically 'undruggable' cancer targets, a move that could redefine oncology.

Ollin Biosciences secured $330M to challenge giants like Roche and Regeneron. Their next-gen antibody shows early promise in treating vision loss.

A massive $115M funding round fuels UK biotech RQ Bio's quest to replace the annual flu shot for the vulnerable with a single, season-long antibody treatment.

After game-changing FDA news for its Huntington's therapy, uniQure's upsized $225M offering signals massive investor confidence and accelerates its mission.

A novel drug designed by AI to prevent a crippling side effect of chemotherapy has received dual US and Taiwan regulatory approval, paving the way for human trials.

Beyond oil, Abu Dhabi is building a global life sciences hub. A new partnership with Sanofi to create a Vaccine Innovation Centre is its boldest move yet.

A new €35,000 grant fuels Canadian gut health research, highlighting a strategic play where corporate philanthropy meets a multi-billion dollar market.

A new partnership integrates AbTherx's elite Atlas™ mouse platform into FairJourney Bio's workflow, promising to slash timelines and boost success rates.

A Miami biotech is pioneering 'off-the-shelf' cell therapies to fight autoimmune and age-related diseases. Can they reset the body's own defenses?

With a $2.74M grant from The Michael J. Fox Foundation, biotech startup X-tosis is advancing a novel therapy that aims to fix the cell's failing powerhouses.

Decades-old treatments for bladder cancer are failing. Now, a wave of gene and viral therapies is sparking a market revolution and offering new hope.

A new alliance arms AI 'agents' with scientific reasoning and supercomputing power, aiming to make drug development faster, smarter, and more trustworthy.

The new SKyvec™ platform promises major productivity gains, positioning the CDMO giant to reshape a market desperate for manufacturing breakthroughs.

A new DOE-funded project pairs engineered microbes with AI to find critical minerals in hours, aiming to slash US foreign dependency and remake mining economics.

A novel drug aims to reverse myelin damage in MS, a feat no current therapy can achieve. But with a recent FDA hold, is Quantum BioPharma's vision a breakthrough or a mirage?

A Canadian biotech is developing a novel cancer drug. We look beyond the paid promotions to analyze the science, the strategy, and the high-stakes reality.